Up 140%: Why Chelsea Therapeutics International Ltd. Is Soaring After-Hours

Why is Chelsea Therapeutics set to soar tomorrow?

Jan 14, 2014 at 7:52PM

The roller-coaster ride never ends for biotech investors.

Last week, we saw shares of Intercept Pharmaceuticals soar 516% on positive results for its experimental NASH drug. However, a press release pointing to some of the drug's side-effects caused shares to pull back this week. Conversely, shares of Chelsea Therapeutics (NASDAQ:CHTP) plummeted 30% on Friday, but are up a whopping 140% in after-hours trading. Chelsea investors seem set for a reversal of fortune -- but what happened, and how can things change so quickly in the biotech space?

A little backstory
The FDA rejected Chelsea Therapeutics' drug Northera back in 2012, but it's under review again for the treatment of certain patients suffering from neurogenic orthostatic hypotension -- a rare type of low blood pressure. In anticipation of today's advisory panel, briefing documents were released on Friday that questioned the drug's long-term efficacy. This sparked a sell-off and suggested that Northera might have few supporters at today's meeting. This didn't turn out to be the case; the panel voted overwhelmingly in favor (16 to 1) of approving the drug. The committee gave its thumbs-up, and Reuters reported that many of the panelists suggested Chelsea carry out additional trials to ensure the drug does have long-term benefits.

It's not over yet
The roller-coaster ride may not be over just yet for shareholders. The advisory committee voted in favor of Northera's approval, but the the vote was also positive just before the FDA rejected the drug in 2012. It's important for biotech investors to remember that the FDA has the final say in these matters and is expected to make its final decision on Feb. 14. This decision is hard to predict, and investors should tread cautiously. Even with the stock soaring after-hours, investors have endured a bumpy few years.

CHTP Chart

CHTP data by YCharts

The growth stock investors can't ignore
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but also your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers